Nitinotes is a clinical-stage company developing a revolutionary treatment for obesity. Its flagship product, the EndoZip, simplifies and speeds up endoscopic gastroplasty procedures, offering a widely available, minimally invasive, and effective solution for over 700 million patients with obesity class I & II for whom traditional bariatric surgery is not an option. EndoZip is an automated and operator-independent, minimally invasive robotic suturing system, for safe and easy delivery of effective restrictive sutures to the stomach wall. Nitinotes is conducting a series of pilot studies in various sites around the world aimed at fortifying both its clinical and economic cases.